Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. This is an exciting, high-profile, and highly visible Program Management opportunity to advance a first-in-Class RAS(ON) Inhibitor through clinical development. The ideal candidate is a very proficient and self-motivated program manager with a solid understanding of drug development. The Director, Program Management partners with the Project Team Leader (PTL) on the translation of program strategy into an efficient execution plan; they understand the competitive landscape and clinical context to manage the cross-functional dependencies and connections. They understand the breadth of cross-functional activities and can foster productive collaborations to ensure successful execution. Overall, the Director, Program Management makes things happen via productive collaborations in an organization that is rapidly developing its capabilities and infrastructure. They not only care about the outcomes but how we get there.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director